HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionHIV-1 neutralizing antibodies: understanding nature's pathwaysVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityA Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway - Adaptation to HIV Envelope ProcessingHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesReducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP TrimersElicitation of HIV-1-neutralizing antibodies against the CD4-binding site.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.Strategies to guide the antibody affinity maturation processDiscrete partitioning of HIV-1 Env forms revealed by viral capture.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer AntigensM48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric unitsDevelopment of prophylactic vaccines against HIV-1.Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticlesImpact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity.Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.Native-like Env trimers as a platform for HIV-1 vaccine design.Humoral immunity in the Friend retrovirus infection model.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Vaccine design: emerging concepts and renewed optimism.HIV-1 vaccine immunogen design strategies.Envelope Glycoprotein Trimers as HIV-1 Vaccine ImmunogensHIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.
P2860
Q26775082-AA9A6BC0-5510-4BA9-AC7C-8B3BB0B3F42FQ27000480-8529F28E-DE22-4F68-95E9-E4C0868E8999Q27319450-855D1CAE-D2D5-4D58-9D85-62D2E5AD5DE6Q27644383-1BF591F8-91D1-4EFC-86C3-2B76F6C8EC8BQ27644515-E2C8B7FB-0B9F-461C-8F1E-B6011CB9204DQ27678306-335A4DE7-3333-49F8-8CA4-B15E19C7B382Q27680125-ACC9E629-B06E-44A9-818D-2EBE44B0A211Q28485983-720CAD72-D863-40EA-BC67-56A59E2B0844Q28533980-3224E425-5C6D-460E-A373-CEF17737023FQ30234773-858035A9-AD9C-4A86-8D75-98DD77B2B6ADQ31132248-94036C50-3AA0-4A4D-B0C0-0DB0EB7DE024Q31151010-698FD7F5-CB5E-46C8-BA59-B801AB940709Q33683203-369D4F48-FF48-49EA-8B6B-CC5C3ED1AE80Q33907694-3662E35B-61D0-46C6-A54A-7FC8CFB44F55Q34133551-3D9726AD-8F45-4C48-9031-07E304519F75Q34172295-21D85F85-BFA5-46A2-8777-F21B5D10540EQ34473958-23C99AC3-7CA4-4C95-92FF-0A76FA2B9761Q34517381-F7EF586F-8D36-451D-8DA5-4B44AFB8CF50Q34611144-EDF000FA-4DFF-4388-BB30-ACAC75D833A5Q35061529-F9D66591-89E0-4D6B-AC72-D6B12098B799Q35641498-7D2064F0-AAC3-4869-B0AB-233135E5920DQ35685300-7656E846-7F94-4ACB-AAD3-1BDB7ADCAFC1Q36088254-4986B0D3-7CBA-48FE-BE71-983F163BD5E4Q36303368-76B6DAAC-0E2A-49C6-8764-8D09EEC2E3A2Q36434196-B5E059D9-A505-4330-AC72-67F8C367968CQ36608485-F2B1C239-F429-417F-B9CA-6E4C0D9D3DACQ36736597-8BCB0249-BB7F-44DA-B1A8-6E8FAB19CC6DQ36911746-5154B62C-EA4E-49F1-8E13-7D9A3880DB33Q37042563-8723E369-279D-43BB-B05F-86C8B5CB37CFQ37060947-3ACF3A54-4D6A-45EC-8729-1EBBFD7CBBE1Q37183472-B26AC27E-A139-4065-9845-0BDAF33EF1AAQ37419199-FD5C775E-68C0-4478-80B0-BFB161E02A29Q37633417-BC5619F9-A0D6-4417-BD09-21A3B51E899EQ37730925-E36CC765-1EC7-42A5-AC8C-DF65F75C0DBAQ38072056-D04BB01C-D47A-4676-82D0-837DB38AA26CQ38087785-A4AEF713-ADD1-4186-BBDD-BCF9143755F6Q38330424-5AC01D8F-78DF-4C5A-938E-A563CC2C66ECQ38581943-A9515DC4-9AFA-4E5B-B40A-D2A04EAA6322Q38665463-0D27E20E-0DC9-4329-8D06-CDD34B9781A3Q38708708-19C51391-DDF9-411D-AF0A-A070B7950274
P2860
HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@en
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@nl
type
label
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@en
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@nl
prefLabel
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@en
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@nl
P2093
P2860
P356
P1433
P1476
HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.
@en
P2093
Ema T Crooks
James M Binley
Keiko Osawa
Tommy Tong
P2860
P304
P356
10.1128/JVI.06938-11
P407
P577
2012-02-01T00:00:00Z